Lisa Ricciardi, Cognition CEO (UDG Healthcare)
NIH — and some familiar players — back a PhII Alzheimer’s gamble in another stab at the amyloid hypothesis
Cognition Therapeutics has a $76 million grant from the NIH to try out its approach to guarding against the synaptic damage behind the cascade of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
